The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Golden Meditech and MD Anderson announce creation of Cellenkos Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

GOLDEN MEDITECH HOLDINGS LTD., a Hong Kong-based healthcare enterprise, and MD Anderson Cancer Center announced the creation of Cellenkos Inc., a start-up enterprise focused on umbilical cord blood derived T-regulatory cellular therapies. Cellenkos, to be based in Houston, is funded with an initial investment of $10 million with warrants to purchase an additional $10 million...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 
By Claire Marie Porter and Paul Goldberg
Guest Editorial

ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology

Cancer care is evolving at an unprecedented pace. Practitioners feel the mounting pressures daily: rising cancer rates—particularly in younger patients—a growing population of older cancer survivors, rapid growth in new care and treatment options, and navigating heightened fiscal constraints and uncertainty. 
By Clifford A. Hudis and Thomas Kurian
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account